Compare Stocks: INDP, KOD, AGIO, and NKTR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$34.19 -2.2%	$34.07	$22.24 ▼ $46.00	$2.09B	0.6	851,950 shs	752,477 shs
INDP Indaptus Therapeutics	$3.77 -5.5%	$1.88	$0.92 ▼ $8.57	$531.64M	1.17	1.47 million shs	624,549 shs
KOD Kodiak Sciences	$31.52 -6.7%	$38.67	$10.94 ▼ $47.84	$2.12B	2.18	665,558 shs	1.05 million shs
NKTR Nektar Therapeutics	$57.66 -5.4%	$71.37	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	1.83 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.23%	+3.76%	+4.75%	-5.55%	-9.72%
INDP Indaptus Therapeutics	-5.51%	+17.45%	+225.00%	+15.64%	+21.22%
KOD Kodiak Sciences	-6.75%	-3.81%	-15.31%	-7.54%	+129.74%
NKTR Nektar Therapeutics	-5.43%	-14.43%	-21.75%	-7.04%	-3.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$34.19 -2.2%	$34.07	$22.24 ▼ $46.00	$2.09B	0.6	851,950 shs	752,477 shs
INDP Indaptus Therapeutics	$3.77 -5.5%	$1.88	$0.92 ▼ $8.57	$531.64M	1.17	1.47 million shs	624,549 shs
KOD Kodiak Sciences	$31.52 -6.7%	$38.67	$10.94 ▼ $47.84	$2.12B	2.18	665,558 shs	1.05 million shs
NKTR Nektar Therapeutics	$57.66 -5.4%	$71.37	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	1.83 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-2.23%	+3.76%	+4.75%	-5.55%	-9.72%
INDP Indaptus Therapeutics	-5.51%	+17.45%	+225.00%	+15.64%	+21.22%
KOD Kodiak Sciences	-6.75%	-3.81%	-15.31%	-7.54%	+129.74%
NKTR Nektar Therapeutics	-5.43%	-14.43%	-21.75%	-7.04%	-3.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.75	22.11% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
KOD Kodiak Sciences	2.57	Moderate Buy	$53.67	70.26% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	140.20% Upside

Current Analyst Ratings Breakdown

Latest INDP, KOD, AGIO, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/21/2026	AGIO Agios Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/21/2026	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $50.00
9/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	AGIO Agios Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/17/2026	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$58.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	37.78	N/A	N/A	$20.46 per share	1.67
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.97 per share	N/A
NKTR Nektar Therapeutics	$55.23M	35.64	N/A	N/A	$4.41 per share	13.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
KOD Kodiak Sciences	-$229.97M	-$4.19	N/A	N/A	N/A	N/A	-273.23%	-85.48%	11/12/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)

Latest INDP, KOD, AGIO, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	KOD Kodiak Sciences	-$0.9565	-$1.05	-$0.0935	-$1.05	N/A	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
INDP Indaptus Therapeutics	N/A	19.49	19.49
KOD Kodiak Sciences	N/A	2.49	2.49
NKTR Nektar Therapeutics	N/A	10.42	10.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
INDP Indaptus Therapeutics	7.06%
KOD Kodiak Sciences	89.06%
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
INDP Indaptus Therapeutics	9.94%
KOD Kodiak Sciences	44.40%
NKTR Nektar Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
KOD Kodiak Sciences	124	62.85 million	34.94 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable

INDP, KOD, AGIO, and NKTR Headlines

Recent News About These Companies

Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating

September 23 at 7:14 PM | marketscreener.comM

Wedbush Cuts Nektar Therapeutics (NASDAQ:NKTR) Price Target to $50.00

September 23 at 8:41 AM | marketbeat.com

Nektar Therapeutics stock falls 9.6 percent as patent case weighs

September 22 at 12:25 AM | ad-hoc-news.deA

Nektar Therapeutics drops as jury deliberates in Eli Lilly patent dispute over Rezpeg

September 22 at 7:25 PM | msn.com

Nektar Therapeutics (NASDAQ:NKTR) Stock Price Down 9.6% - What's Next?

September 22 at 3:19 PM | marketbeat.com

Squarepoint Ops LLC Sells 101,578 Shares of Nektar Therapeutics $NKTR

September 22 at 3:29 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR) and Eli Lilly & Co (LLY)

September 18, 2026 | theglobeandmail.com

Nektar’s Rezpeg Trial Completion Adds a New Catalyst in Alopecia Areata

September 18, 2026 | tipranks.com

Nektar Therapeutics stock gains after Q2 loss narrows

September 18, 2026 | ad-hoc-news.deA

BTIG Research Reaffirms Buy Rating for Nektar Therapeutics (NASDAQ:NKTR)

September 18, 2026 | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Given Buy Rating at BTIG Research

September 16, 2026 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Receives "Buy" Rating from BTIG Research

September 9, 2026 | marketbeat.com

Readystate Asset Management LP Invests $5.94 Million in Nektar Therapeutics $NKTR

September 7, 2026 | marketbeat.com

Zacks Research Has Positive Outlook for NKTR Q3 Earnings

September 7, 2026 | marketbeat.com

Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of "Moderate Buy" from Analysts

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires Shares of 96,061 Nektar Therapeutics $NKTR

September 4, 2026 | marketbeat.com

Braidwell LP Acquires 250,916 Shares of Nektar Therapeutics $NKTR

September 3, 2026 | marketbeat.com

Bank of America Corp DE Raises Holdings in Nektar Therapeutics $NKTR

August 29, 2026 | marketbeat.com

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2026 | prnewswire.com

Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test

August 27, 2026 | finance.yahoo.com

AWM Investment Company Inc. Acquires Shares of 20,925 Nektar Therapeutics $NKTR

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INDP, KOD, AGIO, and NKTR Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$34.19 -0.78 (-2.23%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$34.19 0.00 (0.00%)

As of 07:14 AM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Indaptus Therapeutics NASDAQ:INDP

$3.77 -0.22 (-5.51%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.13 (+3.45%)

As of 07:42 AM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Kodiak Sciences NASDAQ:KOD

$31.52 -2.28 (-6.75%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$31.52 +0.00 (+0.01%)

As of 07:20 AM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Nektar Therapeutics NASDAQ:NKTR

$57.66 -3.31 (-5.43%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$58.66 +1.01 (+1.74%)

As of 07:42 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, KOD, AGIO, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, KOD, AGIO, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, KOD, AGIO, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INDP, KOD, AGIO, and NKTR Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Indaptus Therapeutics NASDAQ:INDP

Kodiak Sciences NASDAQ:KOD

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INDP, KOD, AGIO, and NKTR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INDP, KOD, AGIO, and NKTR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INDP, KOD, AGIO, and NKTR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INDP, KOD, AGIO, and NKTR Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Indaptus Therapeutics NASDAQ:INDP

Kodiak Sciences NASDAQ:KOD

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools